Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review
- 1 June 2019
- journal article
- review article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 92, 1-7
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Drugs for insomniaExpert Opinion on Emerging Drugs, 2012
- Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomniaNeuropharmacology, 2012
- Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational InsomniaNeuropsychopharmacology, 2012
- Increased numbers of orexin/hypocretin neurons in a genetic rat depression modelNeuropeptides, 2011
- Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controlsNeuroscience Letters, 2010
- Increased orexin levels in the cerebrospinal fluid the first year after a suicide attemptJournal of Affective Disorders, 2009
- Orexin Signaling Mediates the Antidepressant-Like Effect of Calorie RestrictionJournal of Neuroscience, 2008
- Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depressionNeuropeptides, 2007
- Arousal and reward: a dichotomy in orexin functionTrends in Neurosciences, 2006
- Hypocretins: Waking, Arousal, or Action?Neuron, 2005